A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer
Phase of Trial: Phase I/II
Latest Information Update: 29 May 2019
Price : $35 *
At a glance
- Drugs Emibetuzumab (Primary) ; Ramucirumab
- Indications Adenocarcinoma; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 29 May 2019 Safety and efficacy results published in the Clinical Cancer Research.
- 28 Mar 2018 Status changed from active, no longer recruiting to completed.
- 01 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History